Skip to main content
. Author manuscript; available in PMC: 2016 Aug 4.
Published in final edited form as: Circulation. 2015 Jun 30;132(5):402–414. doi: 10.1161/CIRCULATIONAHA.115.015884

Figure 6.

Figure 6

Change in LS value from randomization to follow-up (12–18 months) by treatment arm (spironolactone versus placebo) among patients enrolled in (A) the Americas and (B) Russia and Georgia. P for interaction between randomized treatment assignment and change in LS by region=0.09. Baseline-adjusted analysis is based on an ANCOVA. Fully adjusted analysis adjusted for baseline characteristics that differed significantly between treatment arms by region. In the Americas, the multivariable model adjusted for randomization strata (prior hospitalization or natriuretic peptide level), age, race, heart rate, and LVEDVi. In Russia and Georgia, the multivariable model adjusted for randomization strata, history of hypertension, and the presence of significant valvular disease.